Nielsen, S. (2020). Commentary on Cairns et al. (2020): Codeine rescheduling—where to from here? Addiction, 115(3), 460-461. doi:10.1111/add.14881

Nielsen, S., & McAuley, A. (2020). Etizolam: A rapid review on pharmacology, non-medical use and harms. Drug and Alcohol Review, 39(4), 330-336. doi:10.1111/dar.13052

Nielsen, S., Picco, L., Kowalski, M., Sanfilippo, P., Wood, P., Larney, S., Bruno, R., & Ritter, A. (2020). Routine opioid outcome monitoring in community pharmacy: Outcomes from an open-label single-arm implementation-effectiveness pilot study. Research in Social and Administrative Pharmacy. doi:10.1016/j.sapharm.2020.02.009

O'Brien, H., et al., Population patterns in Alcohol Use Disorders Identification Test (AUDIT) scores in the Australian population; 2007–2016. Australian and New Zealand Journal of Public Health, 2020. 44(6): p. 462-467.

O'Keefe, D., Ritter, A., Stoove, M., Hughes, C., & Dietze, P. (2020). Harm reduction programs and policy in Australia: Barriers and enablers to effective implementation. Sucht, 66(1), 33-43. doi:10.1024/0939-5911/a000641

Olsson, C. A., Spry, E., Letcher, P., McAnally, H., Thomson, K., Macdonald, J., . . . Hutchinson, D., McIntosh, J., O’Connor, M., McGee, R., Sanson, A., Hancox, R. J., & Patton, G. C. (2020). The Australian and New Zealand intergenerational cohort consortium: A study protocol for investigating mental health and well-being across generations. Longitudinal and Life Course Studies, 11(2), 267-281. doi:10.1332/175795920X15792720930280

Palamar, J. J., Salomone, A., & Barratt, M. J. (2020). Drug checking to detect fentanyl and new psychoactive substances. Current Opinion in Psychiatry, 33(4), 301-305. doi:10.1097/YCO.0000000000000607

Palmer, A., Scott, N., Dietze, P., & Higgs, P. (2020). Motivations for crystal methamphetamine-opioid co-injection/co-use amongst community-recruited people who inject drugs: A qualitative study. Harm Reduction Journal, 17(1). doi:10.1186/s12954-020-00360-9

Peacock, A., Price, O., Dietze, P., Bruno, R., Salom, C., Lenton, S., Swanton, R., Uporova, J., Karlsson, A., Chan, R., Gibbs, D., Grigg, J., Daly, C., Hall, C., Wilson, T., Degenhardt, L., & Farrell, M. (2020). Impacts of COVID-19 and associated restrictions on people who use illicit stimulants in Australia: Preliminary findings from the Ecstasy and Related Drugs Reporting System 2020. Drug Trends Bulletin Series. Sydney: National Drug and Alcohol Research Centre, UNSW Sydney Retrieved from http://doi.org/10.26190/5ef1628d8e50c

Picco, L., et al., Validation of the OWLS, a Screening Tool for Measuring Prescription Opioid Use Disorder in Primary Care. Pain Med, 2020. 21(11): p. 2757-2764.

Polimanti, R., Walters, R. K., Johnson, E. C., McClintick, J. N., Adkins, A. E., Adkins, D. E., . . . Degenhardt, L., . . . Gelernter, J. (2020). Leveraging genome-wide data to investigate differences between opioid use vs. opioid dependence in 41,176 individuals from the Psychiatric Genomics Consortium. Molecular Psychiatry. doi:10.1038/s41380-020-0677-9

Price, O., Kelly, G., & Peacock, A. (2020). Northern Territory Drug Trends 2019: Key findings from the Ecstasy and Related Drugs Reporting System (EDRS) Interviews. Australian Drug Trends. Sydney: National Drug and Alcohol Research Centre, UNSW Sydney. Retrieved from http://doi.org/10.26190/5e45fc002c71a